Latest News

Stephan Weidinger, MD, PhD, discusses 5-year ADlong data showing durable skin clearance and itch control with lebrikizumab in atopic dermatitis.

Clinicians described how steroid exposure from multiple prescribers shapes biologic decisions in asthma and COPD.

From oral IL-23 blockade in UC to sex-specific FIT thresholds and a swallowable Barrett’s test, these are 7 trials from ACG 2026 clinicians should know.

APPs described earlier recognition of type 2 disease, documentation strategies for payers, and the role of specialty pharmacy in biologic access.

Participants described how they use risk assessment, payer requirements, and patient preference to sequence PAH therapies.

Oral bitopertin met all primary and secondary endpoints in the phase 3 APOLLO trial in EPP, cutting PPIX and increasing pain-free time in light.

Phase 4 VERDICT data show a 67% lower hazard of UC complications with disease clearance versus symptomatic remission among target achievers.

Check out highlights from news published on day 1 of CHEST 2026, spanning asthma, COPD, bronchiectasis, pulmonary rehabilitation, and fibrotic ILD.

Yoseph Dalia, MD, discusses diagnosing and treating pseudofolliculitis barbae, its occupational impact, and barriers to care in skin of color.

Catch up on any data and key clinician perspectives presented at the Heart Failure Society of America Annual Scientific Meeting 2026.

Plasma and exhaled breath sphingolipid signatures differed between IPF and fibrotic hypersensitivity pneumonitis.

A post hoc analysis linked more purulent patient-reported sputum to higher neutrophil elastase activity and greater bronchiectasis disease activity.

Children aged 2 - 11 with atopic dermatitis saw early, lasting itch and sleep gains with nemolizumab through 1 year in phase 2 data shared at PeDRA 2026.

In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL.

Chronic proton pump inhibitor use carried 60% greater odds of asthma exacerbation and nearly 4-fold odds of rescue corticosteroid use in a matched cohort of 2456 patients.

George Washko, MD, discusses a late-breaking OBERON/TITANIA analysis showing tozorakimab reduces segmental mucus plug scores in COPD.

Advanced practice providers described how documentation, specialty pharmacy support, and payer requirements shape biologic selection and timing.

Participants said payer criteria and patient goals often outweigh mechanism when choosing biologics, and that shared decision-making is harder in COPD.

A single Revita procedure preserved about 80% of tirzepatide-induced weight loss at six months in the REMAIN-1 pivotal cohort.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss a major breakthrough with the Twiist insulin pump and the recent ADA/EASD T2D guidelines.

AASLD’s first Expert Practice Opinion adds EUS-guided biopsy and sets no INR or platelet thresholds.

Real-world data from ACG 2026 show elafibranor lowered ALP in patients with PBC who switched from obeticholic acid and in those new to second-line therapy.

Sarina Berger Elmariah, MD, PhD, MPH, discusses 3-year nemolizumab data in early responders and what IL-31 blockade means for itch and atopic dermatitis.